Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
Pre-Market: $29.13 +0.04 (0.14%) 9:12 AM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
Pre-Market: $29.13 +0.04 (0.14%) 9:12 AM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates
by Kinjel Shah
Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.
Pfizer (PFE) RSV Vaccine Found Effective in Older Adults
by Zacks Equity Research
Based on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.
Akero Therapeutics (AKRO) Up on Positive NASH Study Data
by Zacks Equity Research
Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Morphic
by Zacks Equity Research
Pfizer, BioNTech, Moderna and Morphic are included in this Analyst Blog.
Pfizer (PFE), BioNTech Post Data on COVID Jab for Kids Under 5
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) report updated data, showing that their three-dose COVID-19 vaccine is 73.2% effective in children under five years.
Moderna (MRNA) Seeks FDA Nod for Omicron-Based COVID Jab
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID-19 booster vaccine, mRNA-1273.222, is designed to target the Omicron BA.4 and BA.5 subvariants. The vaccine has been developed specifically for the U.S. market.
Moderna (MRNA) to Supply Omicron-based COVID Jab in Canada
by Zacks Equity Research
Moderna's (MRNA) Omicron-specific bivalent vaccine booster is yet to be approved by Canadian health authorities. The government seeks to purchase 12 million doses of the same in 2022.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer (PFE), BioNTech Seek FDA Nod for Omicron Variant Booster
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccine contains mRNA encoding the spike protein present in the original vaccine as well as mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Novavax (NVAX) COVID-19 Vaccine Gets FDA Nod for Adolescents
by Zacks Equity Research
Post the label expansion by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in individuals aged 12 years and older in the United States.
Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down
by Zacks Equity Research
Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.
Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose
by Zacks Equity Research
Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.
Novavax's (NVAX) COVID Vaccine Aids Growth, Overdependence Ails
by Zacks Equity Research
Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.
Should First Trust Rising Dividend Achievers ETF (RDVY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDVY
PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation
by Zacks Equity Research
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023
by Kinjel Shah
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Exelixis (EXEL) Q2 Earnings Beat, Cabometyx Maintains Growth
by Zacks Equity Research
Exelixis (EXEL) tops earnings and sales in the second quarter as lead drug Cabometyx maintains momentum.
Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half
by Zacks Equity Research
Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
by Zacks Equity Research
Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.
Biohaven Pharmaceutical (BHVN) Q2 Earnings Lag, Sales Beat
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. BHVN also reports a wider-than-expected Q2 loss.
Biotech Wins Last Week: 5 Best ETFs
by Sweta Killa
The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.
Zacks Investment Ideas feature highlights: Pfizer, Caterpillar, and Johnson & Johnson
by Zacks Equity Research
Pfizer, Caterpillar, and Johnson & Johnson are part of Zacks Investment Ideas article.
3 Blue-Chip Stocks With Rock-Solid Dividends
by Derek Lewis
Blue-chip stocks are companies that have consistently provided quality, reliability, and the ability to operate profitably in the face of both good and bad times.